U.S. stock abnormal movement | BeiGene (ONC.US) rises more than 3% in the first quarter, the total overseas authorization amount for Chinese innovative drugs hits a new high.

According to the Wise Finance and Economics app, on Wednesday, BeiGene (ONC.US) rose more than 3% to $252.97. It is understood that with the improvement of the research and development capabilities of domestic innovative pharmaceutical companies, more and more companies are beginning to enter the international market. In particular, the amount of out-licensed transactions for Chinese innovative drugs has surged, with a first payment of $3.16 billion in 2024 and a total transaction amount of $51.1 billion. Federal Pharmaceutics, Hengrui Medicine, and other large-scale licensing transactions have set new records, with the global business development (BD) transaction ratio rising to 30%. In the first quarter of 2025, the total amount of overseas licenses again reached a record of $45.5 billion, approaching the level of the entire year 2024.